Abstract
Ten years ago, Velakoulis, the author of a study cited in the present article, was appreciating that the role of functional imaging in schizophrenia research would involve collaboration of clinicians, imaging specialists, and neuropsychologists, and the past year’s literature proves his point. Our review shows that structural and functional imaging in schizophrenia is still alive and well. In the past year, it has focused on changes in “at-risk” and first-episode schizophrenia populations and has been used by researchers to characterize phenotypes of patients with schizophrenia prior to including them in genetic research. A decade ago, O’Donovan and Owen were cautiously optimistic about future advances in finding susceptibility genes for schizophrenia, and this year’s literature, including their review, proves that the massive efforts of research in the genetics of schizophrenia have started to pay off. An almost-obscure area 10 years ago, pharmacogenetics of schizophrenia is well represented in the past year and gives hope to the practicing clinicians who are eagerly waiting to understand patients’ variability in antipsychotic drug response. These and additional areas are included in our review of schizophrenia literature in the past year.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Velakoulis D, Wood SJ, Wong MT, et al.: A magnetic resonance imaging study of chronic schizophrenia, first episode psychosis and ultra-high-risk individuals. Arch Gen Psychiatry 2006, 63:139–149.
Whitworth AB, Kemmler G, Honeder M, et al.: Longitudinal volumetric MRI study in first-and multiple-episode male schizophrenia patients. Psychiatry Res 2005, 140:225–237.
McDonald C, Marshall N, Sham PC, et al.: Regional brain morphometry in patients with schizophrenia or bipolar disorder and their unaffected relatives. Am J Psychiatry 2006, 163:478–487.
Borgwardt S, Radue E, Gotz K, et al.: Radiological findings in individuals at high risk of psychosis. J Neurol Neurosurg Psychiatry 2006, 77:229–233.
Lencz T, Smith CW, McLaughlin D, et al.: Generalized and specific neurocognitive deficits in prodromal schizophrenia. Biol Psychiatry 2006, 59:863–871.
Milev P, Ho B, Arndt S, Andreasen NC: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495–506.
Aleman A, Kahn R: Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol 2005, 77:283–298.
Schneider F, Gur RC, Koch K, et al.: Impairment in the specificity of emotion processing in schizophrenia. Am J Psychiatry 2006, 163:442–447.
Mancini-Marie A, Potvin S, Fahim C, et al.: Neural correlates of affect regulation model in schizophrenia patients with substance use history: a functional magnetic resonance imaging study. J Clin Psychiatry 2006, 67:342–350.
Buckley PF, Dean D, Bookstein FL, et al.: A three-dimensional morphometric study of craniofacial shape in schizophrenia. Am J Psychiatry 2005, 162:606–608.
Donovan-Lepore AM, Jaeger J, Czobor P, et al.: Quantitative craniofacial anomalies in a racially mixed schizophrenia sample. Biol Psychiatry 2006, 59:349–353.
Glaser B, Schumacher J, Williams HJ, et al.: No association between the putative functional ZDHHC8 single nucleotide polymorphism rs175174 and schizophrenia in large European samples. Biol Psychiatry 2005, 58:78–80.
St Clair D, Xu M, Wang P, et al.: Rates of adult schizophrenia following prenatal exposure to Chinese famine of 1959–1961. JAMA 2005, 294:557–561.
Neugebauer R: Accumulating evidence for prenatal nutritional origins of mental disorders. JAMA 2005, 294:621–623.
Craddock N, O’Donovan MC, Owen MJ: The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 2005, 42:193–204.
Suarez BK, Duan J, Sanders AR, et al.: Genomewide linkage scan of 409 European ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3–p21.2 and 11p13.1–q14.1 in the combined sample. Am J Hum Genet 2006, 78:315–333.
Hallmayer JF, Kalaydjieva L, Badcock J, et al.: Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. Am J Hum Genet 2005, 77:468–476.
Kirov G, O’Donovan M, Owen MJ: Finding schizophrenia genes. J Clin Invest 2005, 115:1440–1448.
DeRosse P, Funke B, Burdick KE, et al.: Dysbindin genotype and negative symptoms in schizophrenia. Am J Psychiatry 2006, 163:532–534.
Duan J, Martinez M, Sanders AR, et al.: Neuregulin 1 (NRG1) and schizophrenia: analysis of a US family sample and the evidence in the balance. Psychol Med 2005, 35:1599–1610.
Kim JW, Lee YS, Cho EY, et al.: Link age and association of schizophrenia with genetic variations in the locus of neuregulin 1 in Korean population. Am J Med Genet B Neuropsychiatr Genet 2006, 141:281–286.
Fukui N, Muratake T, Kaneko N, et al.: Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population. Neurosci Lett 2006, 396:117–120.
Gardner M, Gonzalez-Neira A, Lao O, et al.: Extreme population differences across Neuregulin 1 gene, with implications for association studies. Mol Psychiatry 2006, 11:66–75.
Law AJ, Lipska BK, Weickert CS, et al.: Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5′ SNPs associated with the disease. Proc Natl Acad Sci U S A 2006, 103:6747–6752.
Burdick KE, Hodgkinson CA, Szeszko PR, et al.: DISC1 and neurocognitive function in schizophrenia. Neuroreport 2005, 16:1399–1402.
Callicott JH, Straub RE, Pezawas L, et al.: Variation of DISC1 affects hippocampal structure and function and increases risk of schizophrenia. Proc Natl Acad Sci U S A 2005, 102:8627–8632.
Gourion D, Goldberger C, Leroy S, et al.: Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. Neuroreport 2005, 16:1407–1410.
Hirvonen J, van Erp TG, Huttunen J, et al.: Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia. Arch Gen Psychiatry 2005, 62:371–378.
Friedman JH: Historical perspective on movement disorders. J Clin Psychiatry 2004, 65(Suppl 9):3–8.
Lieberman JA, Stroup TS, McEvoy JP, et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209–1223.
Miller DD, Ellingrod VL, Holman TL, et al.: Clozapine-induced weight gain associated with the 5HT2C receptor-759C/T polymorphism. Am J Med Genet B Neuropsychiatr Genet 2005, 133:97–100.
Buckland PR, Hoogendoorn B, Guy CA, et al.: Low gene expression conferred by association of an allele of the 5HT2C receptor gene with antipsychotic-induced weight gain. Am J Psychiatry 2005, 162:613–615.
Lencz T, Robinson DG, Xu K, et al.: DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. Am J Psychiatry 2006, 163:529–531.
de Leon J, Susce MT, Pan RM, et al.: The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse effects and discontinuation. J Clin Psychiatry 2005, 66:15–27.
Perlis RH, Ganz DA, Avorn J, et al.: Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol 2005, 25:427–434.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Foster, A., Usman, M., Stirewalt, E. et al. Schizophrenia: From brain morphology to psychopathology. Curr Psychiatry Rep 9, 337–342 (2007). https://doi.org/10.1007/s11920-007-0042-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11920-007-0042-6